{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:54:33Z","timestamp":1782316473898,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.112014","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T06:17:40Z","timestamp":1712989060000},"page":"112014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combination of chidamide and PD-1 blockade in Refractory\/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-8596","authenticated-orcid":false,"given":"Zhenhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-9998","authenticated-orcid":false,"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-8907","authenticated-orcid":false,"given":"Zhenya","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2024.112014_b0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10254","key":"10.1016\/j.intimp.2024.112014_b0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112014_b0025","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2024.112014_b0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.20.01749","article-title":"Chimeric antigen receptor T-cell therapy in the management of relapsed non-hodgkin lymphoma","volume":"39","author":"Komanduri","year":"2021","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.intimp.2024.112014_b0040","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112014_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.112014_b0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcyt.2022.10.001","article-title":"Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19\/CD22 in refractory\/relapsed transformed aggressive B-cell lymphoma","volume":"25","author":"Xu","year":"2023","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.intimp.2024.112014_b0055","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1002\/ctm2.176","article-title":"Long-term outcomes of relapsed\/refractory double-hit lymphoma (r\/r DHL) treated with CD19\/22 CAR T-cell cocktail therapy","volume":"10","author":"Wei","year":"2020","journal-title":"Clin Transl Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112014_b0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","article-title":"Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract","volume":"22","author":"Zeng","year":"2020","journal-title":"Cytotherapy"},{"issue":"17","key":"10.1016\/j.intimp.2024.112014_b0070","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2024.112014_b0075","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2024.112014_b0080","doi-asserted-by":"crossref","first-page":"10052","DOI":"10.1200\/JCO.2020.38.15_suppl.10052","article-title":"Preclinical and clinical studies of a class I\/IV HDAC inhibitor, mocetinostat, in melanoma","volume":"38","author":"Weber","year":"2020","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2024.112014_b0085","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1200\/JCO.2021.39.15_suppl.9545","article-title":"Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy","volume":"39","author":"Hassel","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112014_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904497","article-title":"CAR T-cell therapy predictive response markers in diffuse large B-cell lymphoma and therapeutic options after CART19 failure","volume":"13","author":"Caballero","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2022.09.009","article-title":"Clinical and radiographic predictors of progression and survival in relapsed\/refractory lymphoma patients receiving anti-CD19 CAR t-cell therapy","volume":"23","author":"Jodon","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"27","key":"10.1016\/j.intimp.2024.112014_b0100","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112014_b0105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.intimp.2024.112014_b0110","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112014_b0115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol."},{"issue":"14","key":"10.1016\/j.intimp.2024.112014_b0120","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/1078-0432.CCR-19-3888","article-title":"Dissecting the tumor-immune landscape in chimeric antigen receptor T-cell therapy: Key challenges and opportunities for a systems immunology approach","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2024.112014_b0125","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.intimp.2024.112014_b0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112014_b0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jtct.2021.02.005","article-title":"Predicting outcomes following anti-CD19 CAR T cell therapy in aggressive B cell lymphomas","volume":"27","author":"Ho","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112014_b0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"27","key":"10.1016\/j.intimp.2024.112014_b0145","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112014_b0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtct.2022.05.043","article-title":"ASTCT committee on practice guidelines survey on evaluation & management of diffuse large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112014_b0155","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2021-147433","article-title":"Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy","volume":"138","author":"Zurko","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.intimp.2024.112014_b0165","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: The darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol Rev."},{"issue":"21","key":"10.1016\/j.intimp.2024.112014_b0175","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112014_b0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood-2021-145764","article-title":"Impact of molecular features of diffuse large B-cell lymphoma on treatment outcomes with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy","volume":"138","author":"Hill","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2024.112014_b0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2024.112014_b0190","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112014_b0195","doi-asserted-by":"crossref","first-page":"20637","DOI":"10.1038\/s41598-021-00227-4","article-title":"Upregulation of CD22 by Chidamide promotes CAR T cells functionality","volume":"11","author":"Yang","year":"2021","journal-title":"Sci Rep."},{"key":"10.1016\/j.intimp.2024.112014_b0200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112014_b0205","first-page":"4415","article-title":"CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112014_b0210","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2024.112014_b0215","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3324\/haematol.2021.278461","article-title":"PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response","volume":"106","author":"Zurko","year":"2021","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.intimp.2024.112014_b0220","doi-asserted-by":"crossref","first-page":"39003","DOI":"10.1021\/acsami.1c08290","article-title":"Combination of chidamide-mediated epigenetic modulation with immunotherapy: Boosting tumor immunogenicity and response to PD-1\/PD-L1 blockade","volume":"13","author":"Tu","year":"2021","journal-title":"ACS Appl Mater Interfaces."},{"key":"10.1016\/j.intimp.2024.112014_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-gamma response in NK-T cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"EBioMedicine"},{"issue":"19","key":"10.1016\/j.intimp.2024.112014_b0230","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.12998\/wjcc.v10.i19.6555","article-title":"Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy","volume":"10","author":"Hao","year":"2022","journal-title":"World J Clin Cases."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T20:04:18Z","timestamp":1715630658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924005320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":46,"alternative-id":["S1567576924005320"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112014","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of chidamide and PD-1 blockade in Refractory\/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112014"}}